[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572405":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":26,"responsibleParty":39,"collaborators":41,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"ART Fertility Clinics LLC","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Normo-ovarian response patients who undergo an IVF treatment including PGT-A",null,"Patients will follow the stimulation protocol outlined below:\n\nInitial doses will be based on ovarian reserve parameters, with the starting dosage identical for both stimulation cycles (Gonal-F® or hMG):\n\nDose adjustments may be made starting from day 6 Antagonist suppression will be fixed from day 5 onwards Final oocyte maturation will be triggered with a dual trigger: 2,500 IU urinary hCG and 0.3 mg Decapeptyl.",[13],{"name":14,"affiliation":5,"role":15},"Barbara Lawrenz, PhD","STUDY_DIRECTOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Daniela Nogueira","CONTACT","971504374961","daniela.nogueira@artfertilityclinics.com",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":25},"Jonalyn DV Edades","+971526408688","jonalyn.ededas@artfertilityclinics.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":10,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"ART Fertility Clinics","RECRUITING","Abu Dhabi","Abu Dhabi Emirate","United Arab Emirates",{"type":34,"coordinates":35},"Point",[36,37],54.39696,24.45118,{"lat":37,"lon":36},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[42],{"name":43,"class":44},"Merck Sharp & Dohme LLC","INDUSTRY","100572405",false,"NCT06732843","Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?","rFSH and hMG","Inclusion Criteria:\n\n1. Maternal age 18 - 38 years\n2. Patients requested PGT-A\n3. BMI 18- 30kg\u002Fm2\n4. Expected normoresponders\n5. Fresh autologous ejaculate (≥5 mill\u002Fml)\n6. Sperm abstinence: 2-3 days\n7. Normal female\u002Fmale karyotype\n8. Regular menstrual cycle length: 25-32 days\n9. AFC of 5-10 in each ovary at the beginning of the stimulation\n10. Trigger: dual trigger: 2.500 IU urinary hCG + 0.3 mg Decapeptyl. (13)\n11. A wash-out period between 1 to 3 months; an inter-cycle variation of 10% in AFC, measured by the same physician, is accepted.\n12. Couple agrees to perform two stimulations before continuing with embryo transfer\n\nExclusion Criteria:\n\n* 1\\. Uterine abnormalities as diagnosed by ultrasound 2. Any hormonal or oral contraceptive pretreatment of 3 months preceding the treatment 3. Endometriosis according to American Fertility Society (AFS) ≥3 4. ≥ 2 miscarriages 5. Bologna criteria poor responders (14)",true,"FEMALE","18 Years","38 Years",{"count":56,"type":57},10,"ESTIMATED","60 Months","OBSERVATIONAL","Gonal-F® (follitropin alfa) is a recombinant FSH without LH activity, while Menopur® contains both LH and hCG. The MEGASET trial compared Menopur® and Gonal-F® in GnRH antagonist cycles with SET, showing similar efficacy. A subsequent study (MEGASET-HR) in high responders found ongoing pregnancy rates of 35.5% for Menopur® and 30.7% for Gonal-F®, with a lower early pregnancy loss for Menopur® (14.5% vs 25.5%).\n\nTelomere length (TL) in oocyte cumulus cells (CC) correlates with oocyte quality and embryo outcomes. This study aims to assess whether stimulation type (hMG vs. Gonal-F) affects TL in CC and subsequent blastocyst development. A randomized, open-label, cross-over study in normo-responders will analyze telomere length, embryo quality, and hormonal markers.",[62,63,64],"OVARIAN STIMULATION","Telomere Length","Telomere Length, Mean Leukocyte",[66,67,68,69,70,71,72,73,74,75],"recombinant human follicle-stimulating hormone (rFSH)","uman-menopausal-gonadotropin (hMG","ocyte quality","embryo quality","blastocyst development","Menopur","GonalF","GnRH antagonist cycles","trophectoderm","cumulus cells","2025-07-24",{"date":78,"type":79},"2025-07-25","ACTUAL",{"date":81,"type":79},"2025-07-23",{"date":83,"type":57},"2027-07-31",{"name":5,"class":6},1]